IMC Chicago’s Avadel Pharmaceuticals AVDL Stock Holding History

IMC Chicago’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,900	Closed	-$1.2M	–	5700
2025 Q4	$1.2M	Sell	55,900 -6,800	-11%	-$132K	﹤0.01%	2834
2025 Q3	$957K	Buy	62,700 +26,200	+72%	+$341K	﹤0.01%	2746
2025 Q2	$323K	Sell	36,500 -6,000	-14%	-$52.7K	﹤0.01%	3074
2025 Q1	$333K	Sell	42,500 -4,600	-10%	-$38.5K	﹤0.01%	2869
2024 Q4	$495K	Buy	47,100 +22,700	+93%	+$276K	﹤0.01%	2765
2024 Q3	$320K	Buy	+24,400	New	+$372K	﹤0.01%	2615

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

IMC Chicago's AVDL Position: Q4 2025 in Review

IMC Chicago sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 30,555 shares — an estimated $593K sold.

IMC Chicago first reported a position in AVDL in Q4 2024 and held it in 4 quarters. The position peaked at $769K in Q4 2024. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

IMC Chicago reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
IMC Chicago sold 30,555 Avadel Pharmaceuticals shares in Q4 2025, an estimated $593K.
IMC Chicago first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 4 quarters.
IMC Chicago's Avadel Pharmaceuticals position peaked at $769K in Q4 2024.
207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.